In this case report and review of 12 additional cases with concurrent CALR-mutation and BCR-ABL1 fusion, we highlighted the importance of integrated clinical, morphologic, and molecular genetic data for classifying atypical myeloid neoplasms for treatment and responses of patients. This evidence concerns the gene BCR and myeloid neoplasm.